Case Page


Case Status:    ONGOING    
On or around 08/19/2016 (Ongoing date of last review)

Filing Date: August 17, 2016

According to a law firm's press release, on July 27, 2016, the Company and LabCorp issued a joint press release announcing that they entered into a definitive agreement and plan of merger (the “Merger Agreement”) under which LabCorp would acquire all of the outstanding shares of Sequenom in a cash tender offer for $2.40 per share (the “Tender Offer), representing a total enterprise value of approximately $371 million, including net indebtedness. The press release further states that the Board approved the Merger Agreement and the terms of the Tender Offer, and recommends that the Company’s stockholders tender their shares. The Tender Offer commenced on August 9, 2016, and is scheduled to expire at 12:01 a.m. Eastern time on September 7, 2016 (the “Expiration Date”), unless the Tender Offer is extended.

The Complaint alleges that the Proposed Transaction is the result of an unfair process and provides the Company’s stockholders with inadequate consideration. The Complaint alleges that inadequacy of the $2.40 per share Tender Offer price is evidenced by the fact that just over a year before the Proposed Transaction was announced, Sequenom shares traded in the $4.00 per share range. The Complaint also alleges that Sequenom has introduced new products, expanded its market reach and executed a corporate restructuring strategy that resulted in a substantial financial turnaround. However, the Complaint alleges that the Board, knowing that the inadequate price and opportunistic timing of the Proposed Transaction would draw serious interest from other potential buyers, and in an effort to ensure that the Proposed Transaction is consummated, agreed to include certain provisions in the Merger Agreement that unreasonably inhibit potential third party bidders from launching topping bids, including: (i) a strict no-solicitation provision that severely constrains the Individual Defendants’ ability to communicate with potential buyers who wish to submit or have submitted unsolicited alternative proposals; (ii) an information rights provision that provides LabCorp with unrestricted access to information about other potential bids, gives LabCorp five business days to match any competing offer that may be made, and gives LabCorp the perpetual right to attempt to match any competing bid; and (iii) a termination fee provision requiring the Company to pay $10.6 million (or nearly 3% of the total value of the Proposed Transaction, based on the $371 million enterprise value of the transaction) to LabCorp in the event that the Company receives a higher offer and enters into an alternative transaction.


Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: United States


Ticker Symbol: SQNM
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data

"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: S.D. California
DOCKET #: 16-CV-02084
JUDGE: Hon. John A. Houston
DATE FILED: 08/17/2016
CLASS PERIOD END: 08/17/2016
  1. Faruqi & Faruqi LLP (Los Angeles)
    10866 Wilshire Boulevard Suite 1470, Faruqi & Faruqi LLP (Los Angeles), CA 90067
    (424) 256-2884 (424) 256-2885 ·
  2. Monteverde & Associates PC
    350 Fifth Avenue, 59th Floor, Monteverde & Associates PC, NY 10118
    (212) 971-1341 ·
No Document Title Filing Date